Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma
CONCLUSIONS: The administration of the reduced dose of methotrexate seems to not compromise treatment success nor increase the risk of CNS recurrence in high-risk BL without CNS involvement. The limitation of the study is that it is not randomized. Our treatment scheme might be considered for centers without methotrexate measurement facility.PMID:34449146 | DOI:10.24953/turkjped.2021.04.011
Source: The Turkish Journal of Pediatrics - Category: Pediatrics Authors: Sema Vural Dildar Bahar Gen ç Rejin Kebudi Öner Doğan Serap Karaman Source Type: research
More News: Burkitt Lymphoma | Chemotherapy | Hodgkin's Disease | Lymphoma | Methotrexate | Non-Hodgkin's Lymphoma | Pediatrics | Study | Toxicology | Turkey Health | Vitamin B9